Coming Soon

Coming Soon

Miriam Bornhorst is an associate professor with a joint appointment at Northwestern University and Lurie Children’s Hospital of Chicago. Her main clinical interests are cancer predisposition (including Neurofibromatosis) and Neuro-Oncology. Her research focuses on discovery of biomarkers that lead to improved treatment of children with cancer. She is currently studying how MEK-inhibitor treatment affects metabolism in children with NF1, with the goal to identify biomarkers that can be used to predict response to treatment, as well as gain a better understanding of how diet affects tumor growth. She is also investigating novel and low allele fraction genomic changes within pediatric brain tumors using optical genome mapping.

Coming Soon

Coming Soon

Alka Chaubey is double board-certified in clinical cytogenetics/genomics and clinical molecular genetics/genomics by the American Board of Medical Genetics and Genomics (ABMGG). Previously, she was the Head of Cytogenomics at PerkinElmer Genomics, where Dr. Chaubey led the successful development and launch of several innovative products including the CNGnome test (low-pass whole genome sequencing), and a new FSHD assay utilizing Saphyr. She has also played an integral role on Vanadis team at PerkinElmer in their efforts to bring a new PCR-free NIPT technology to the market. Prior to PerkinElmer Genomics, Dr. Chaubey was the Director of the Cytogenomics Laboratory at the Greenwood Genetic Center, SC, USA. She also holds an academic appointment as the Scientific Director of the Georgia Esoteric and Molecular Laboratory, Scientific Director of the Cytogenetics Laboratory of the Augusta University Medical Center and Adjunct Assistant professor of Pathology of the medical College of Georgia at Augusta University. Dr. Chaubey serves on the Board of Directors for the Cancer Genomics Consortium and is also the Genetics Subdivision Nominating Committee representative of the Association of Molecular Pathologists (AMP). She originally received her Doctorate degree (PhD) from Guru Nanak Dev University, Amritsar, India and completed her post-doctoral studies at Center for Cellular and Molecular Biology (CCMB), Hyderabad, India, and University of Illinois at Chicago (UIC).

Coming Soon

Coming Soon

Adrian M. Dubuc, Ph.D., FACMG is the Vice-Chair for Clinical Research (Cytogenetics/Genomics) and the Director of the Clinical Cytogenetics Laboratory at Roswell Park Comprehensive Cancer Center. He is an ABMGG-certified Cytogeneticist and Molecular Geneticist who has spent his career attempting to bridge the gap between research innovation and integration of genomic studies into clinical care. Dr. Dubuc has published over 80-peer reviewed publications and contributed to numerous practice guidelines, including American College of Medical Genetics (ACMG) evidence-based guidelines and quality assurance measures. His work has been recognized through >50 talks at national and international meetings, as well as leadership positions, including serving as the President of the Cancer Genomics Consortium.

Coming Soon

Alex Hastie is a PhD trained scientist who has focused on scientific advances in optical genome mapping for the past 12 years. Alex received training during his PhD in cancer genetics, biochemistry, and biophysics at the Roswell Park Cancer Institute. He focused his research on novel technology and received a patent as coinventor for a method for detection of protein-protein interactions. After a post-doctoral fellowship at the Max Planck Institute in Munich, Germany, he joined Bionano Genomics as a scientist, where he has been an inventor on multiple patents and coauthored over 90 peer reviewed publications. Currently, Alex serves as vice president of clinical and scientific affairs where he leads clinical trials and the company’s scientific publication portfolio.

Dr. Madhuri Hegde, FACMG, is the SVP and Chief Scientific Officer of Revvity, responsible for setting the strategic scientific direction of the Company. As both a medical geneticist and American Board of Medical Genetics and Genomics (ABMGG) certified diplomat in clinical molecular genetics, Madhuri is also the head of Revvity Omics and its global network of laboratories offering innovative, omics-based services in more than 155 countries worldwide. Madhuri is a passionate and perpetually curious leader whose team is committed to delivering cutting-edge products to Revvity customers, while keeping a close eye on innovation and bringing those developments to market. Madhuri is energized by bringing people and teams together to make a difference and harness science to positively impact human health. Making the switch from academia to industry in 2016, Madhuri joined Revvity from Emory University in Atlanta, where she served as Executive Director of the Emory Genetics Laboratory and as a professor of human genetics and pediatrics. Before that, she spent several years at the Baylor College of Medicine where she was faculty in the Department of Human Genetics and Director at Baylor Medical Laboratories. She also served several years as a laboratory director at Auckland City Hospital in New Zealand. Madhuri currently serves on the board and is an officer of the American College of Medical Genetics and Genomics Foundation (ACMGF), and leads the ACMG’s International Outreach and Engagement Committee. She is also a member of the ABMGG Board of Directors, serves on Coriell Cell Repositories NIGMS Human Genetic Cell Repository Scientific Advisory Committee, co-chairs ClinGen’s PTEN committee and is a member of the NHGRI ClinGen Hereditary Cancer Executive Committee. She is an adjunct professor of Pediatrics at Emory University School of Medicine and at Georgia Institute of Technology; has either authored or co-authored over 150 peer-reviewed publications and eight book chapters; and presented well over 100 keynote and other invited presentations at major national and international conferences. Exposed to science and the field of genetics at an early age, Madhuri’s decision to pursue a career in this field was heavily influenced by academics and other scientists in her family. She was born and raised in India and earned her bachelor’s and master’s degrees in microbiology at the University of Mumbai. Madhuri also holds a PhD in applied biology and genetics from the University of Auckland, and completed her postdoctoral studies and ABMGG certification at Baylor College of Medicine.

Coming Soon

Dr. Ravindra Kolhe is a Professor and Leon Henri Charbonnier Endowed Chair in Pathology at Augusta University and is the inaugural Associate Dean for translation research at the Medical College of Georgia. He also serves as the Associate Cancer Center Director for Genomics at the Georgia Cancer Center. Currently, Kolhe leads an NCI-designated translational pathology laboratory for MATCH testing which is focused on comprehensive genomic testing in oncology. He co-founded a consortium (SEQUOIA) of 40+ clinical laboratories across the globe for the democratization of NGS testing in oncology & successfully helped multiple labs to bring NGS testing in-house. He served on the Georgia Governor's Task Force for COVID-19 and successfully led the COVID-19 screening program for the State of Georgia during the early Pandemic. Kolhe is also a co-founder of a COVID-19 Host Genome Structural Variation Consortium and coordinated a global network of researchers who are contributing to our collective knowledge on host genome response to the SARS-CoV-2 infection and COVID-19 disease. He has led several studies, focused on adapting and validating newer technologies (NGS, RNA-seq, OGM, etc) in CLIA laboratories by establishing PLA & Z-codes and reimbursement. He has authored more than 90+ peer-reviewed publications and serves on multiple national committees and scientific advisory boards for numerous profit and non-profit organizations.

Coming Soon

Andy Pang received his PhD from the University of Toronto. He is a Senior Staff Scientist in Bioinformatics in the Clinical Affairs department of Bionano. Andy's work involves developing bioinformatic, data science and statistical workflows for clinical applications, and coordinating the participation in structural variation scientific consortia.

Coming Soon

More information coming soon!

Tanushi received her degree in Chemistry from the University of California, Berkeley and attended Johns Hopkins University for a Masters in Biomedical Engineering. She worked at the Stanford School of Medicine studying the mechanism of Fatty Liver Disease using CRISPR-Cas9. Prior to Bionano, Tanushi worked at Synthego, a gene editing biotech in Redwood City, CA managing their synthetic guide portfolio. She currently works at Bionano as the product manager for the Sample Preparation portion of Bionano's workflows.

Coming Soon

Coming Soon

Daniel Saul is a director of product management software and informatics, at Bionano. Daniel has more than 10 years working in the cytogenomics industry after holding positions in several cytogenetics laboratories. Daniel obtained a MS in Biotechnology from the Johns Hopkins University and a M.B.A. from the University of Maryland.

Saumyaa is a senior scientist at AstraZeneca, Sweden. She focuses on assessing and ensuring the safety of AstraZeneca’s Gene Therapy and Engineered Cell Therapy drug candidates. Before this role, she served as a single-cell omics specialist at Astra. She has a background in Immunology and NGS, from her academic research in the USA. She did her Ph.D. in Immunology and her postdoctoral research in Onco-Immunology at Stanford University.

Dr. Smith is an Assistant Professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto. He completed his Clinical Cytogenetics training with the Canadian College of Medical Geneticists (CCMG) in 2010 and added certification in Clinical Molecular Genetics with the CCMG also in 2018. Dr. Smith is Fellow of the American College of Genetics and Genomics, a certified Laboratory Geneticist by the European Board of Medical Genetics and a member of the Cancer Genomics Consortium. Dr. Smith has been developing Optical Genome Mapping for use in Hematologic Malignancies since March of 2021. Dr. Smith is recognized as a national and international leader in the development of OGM for clinical use. He currently leads an International Working Group comprised of more than 20 scientists from 6 different countries (including Canada, United Stats, Belgium, The Netherlands, Spain and Finland) working on the issues towards a uniform clinical implementation of OGM for Hematologic Malignancies.

Marc-Henri Stern received his doctorate in medicine and his PhD in Sciences (immunology) from the universities of Paris. After his postdoctoral training at N.C.I. (USA), he began his research team at Saint Louis Hospital, Paris, on leukemogenesis and DNA repair defects. He joined the Curie Institute in 2000, setting up his team in the Inserm unit U830 unit led by Dr. Olivier Delattre, maintaining a medical activity within the Oncogenetics unit led by Prof. Dominique Stoppa-Lyonnet. His team is dedicated to unravelling the genetic factors of tumor predisposition and of oncogenesis in adult tumors, including breast and ovarian carcinomas and uveal melanoma, ranging from fundamental and translational research to diagnosis. An important contribution of his team was to better define genomic instability in breast and ovarian cancers impaired for BRCA1 or BRCA2, using initially SNP-arrays and presently low coverage Whole Genome Sequencing and Optical Genome Mapping. The defined genomic signature of homologous recombination defect is currently used in clinics. Marc-Henri Stern is currently Senior Research Director at INSERM (DRCE) and team leader at Institut Curie, Paris. He has mentored 18 PhD students (14 who successfully defend their thesis and 4 ongoing students) and 8 post-docs.

Roger E. Stevenson, MD, is a pediatrician and geneticist who founded the Greenwood Genetic Center in South Carolina. After 47 years he left the Center and became a consultant for Bionano Genomics. He has authored multiple editions of three medical textbooks (The Fetus and Newly Born Infant: Influences of the Prenatal Environment; Human Malformations and Related Anomalies; X-Linked Intellectual Disability Syndromes) and over 250 peer-reviewed publications. He set up a statewide system of genetics clinics in South Carolina, initiated a statewide system for surveillance and prevention of neural tube defects, and co-organized meetings on Fragile X syndrome and related disabilities and Malformations and Morphogenesis for clinicians, researchers and trainees.

Dr. Guilin Tang is an Associate Professor and Section Chief of Clinical Cytogenetics in the Department of Hematopathology at the University of Texas MD Anderson Cancer Center (MDACC), and the Medical Director of Cytogenetics program of School of Health Professions at MDACC. She is board certified in Anatomic and Clinical Pathology and Hematopathology by American Board of Pathology, and Clinical Cytogenetics by the American Board of Medical Genetics and Genomics. Dr. Tang's clinical expertise includes diagnosis of hematologic neoplasms (leukemias, lymphomas, and myeloma) and cancer cytogenetics. Her major research interests include characterization and risk stratification of cytogenetic abnormalities in various types of hematological malignancies, discovery and characterization of novel cytogenetic abnormalities and their association with clinicopathologic features. She is also interested in characterization of clinically indolent cytogenetic clones, especially those emerged following cytotoxic therapies. During her academic career, she has published over 230 peer-reviewed original studies. Dr. Tang is a current committee member of the CAP/ACMG Cytogenetics Committee. She has served on Editorial Board of Modern Pathology and is a reviewer for more than 15 prestigious journals.

Professor Deborah Tweddle is an Honorary Consultant in Paediatric and Adolescent Oncology at the Great North Children’s Hospital (GNCH) and Professor of Paediatric Oncology in the Newcastle University Centre for Cancer within the Translational & Clinical Research Institute at Newcastle University. Professor Tweddle has a specific interest in childhood neuroblastoma research – biological, translational and clinical – which she has specialised in for over 20 years. As a clinical academic in paediatric oncology, Professor Tweddle spends most of her time at Newcastle University supervising her research team or undertaking duties related to the VIVO biobank, a national biobank of samples from children and young people with cancer and leukaemia for which she is the Scientific Director. The remainder of her time is spent looking after patients with neuroblastoma at the GNCH and co-directing the National Neuroblastoma Molecular Genetics Reference centre service with her NHS cytogenetics colleagues. Professor Tweddle has particular research interests in the genetics of neuroblastoma, liquid biopsies, pre-clinical drug development, new neuroblastoma models and the epidemiology of relapsed neuroblastoma.

John Yu is Distinguished Chair Professor/Director, Institute of Stem Cell and Translational Cancer Research, CGMH. He is also Distinguished visiting research fellow at Institute of Cellular & Organismic Biology, Academia Sinica, and was the Director for the same Institute (2002-2009). He is the founding President for Taiwan Society for Stem Cell Research. Dr. Yu was elected to serve in committees of International Society for Stem Cell Research USA, Steering Committee of Asia-Pacific Stem Cell Network, scientific advisors for stem cell biology in Kumamoto University, and Ministry of Science and Technology and Ministry of Health and Welfare in Taiwan. He was Director of Exp. Hematology (1998-2002) at Scripps Research Institute, La Jolla, Ca.. He obtained M.D. degree in medicine from National Taiwan University, Ph.D. degree in Biophysics from University of Chicago, and served as biology fellow in the Biolab at Harvard University. He received Established Investigatorship Award from American Heart Assoc. and many other awards in Taiwan.

Coming Soon

Dr. Zou is a Director of the Cytogenetics and Cytogenomics Laboratory at The Johns Hopkins Hospital, Director of the Cancer Cytogenetics Laboratory, Director of Cytogenomic Research Core, and Associate Director of Molecular Diagnostics Laboratory, Johns Hopkins Genomics. Her areas of clinical expertise include the diagnosis of genetic abnormalities in patients with cancer or congenital diseases. Dr. Zou is an expert in cytogenetics and clinical molecular genetics. She is interested in the development of clinical cytogenomic and molecular genetics laboratory tests that can be used in the clinical setting for better patient care, personalized medicine, as well as for discovering disease variants and novel cancer biomarkers. She has been involved in multiple clinical trials. Dr. Zou has published more than 100 peer-reviewed journal articles. As a member of the American Board of Medical Genetics and Genomics, Dr. Zou is active in the training of residents and fellows in several training programs, as well as students for clinical cytogenetics, molecular genetics, pharmaco-genomics and personalized medicine. She was recognized with The Best Attending Pathologist Teacher in Clinical Pathology by University of Maryland in 2017-2018. She is an active committee member of professional societies such as American College of Medical Genetics and Genomics (ACMG), Association for Molecular Pathology (AMP), College of American Pathologists (CAP), Cancer Genomics Consortium (CGC), and Association of Genetic Technologists (AGT), etc., as well as an editor, board member, and associate editor for several professorial journals.